Hi Mia! Welcome. I'm a non-responder to the previous treatment. Geno 1a, same as you. I'm on Victrelis and I'm happy that my doc & I chose that drug for me. The SVR rates are approximately the same between both drugs. It's not an easy treatment no matter which path you take, but according to the experiences related on this forum, Victrelis has fewer side effects but a longer treatment duration. I just found out that I am undetectable after only 4 weeks on the Vic, I never thought I would see the day!!! Incidentally, I just spoke to my doc about this, and all 5 of his patients currently on Victrelis have had their viral load drop to undetectable by that 4 week mark. So please don't fret if you get "stuck" doing that drug due to insurance reasons. It's working for us non-responders! Best of luck and feel free to ask any questions, we're all here for you. aloha.
-Kim
news said
Apr 11, 2012
Mia, I am not aware of any obviously better performance from Incivek or Victrelis. That is not to say that there aren't minor differences, but the folks around here that are using Victrelis are enjoying incredible success rates, without many of the more objectionable side effects from Incivek. I am an Incivek veteran, and I would rather be poked in the eye than go through that again. It worked great, but it hurt me.
Alan
Mia DAngelo said
Apr 10, 2012
I am a non-responder x2. My last bx (biopsy) was approximately one month ago. Bx reveals stage 3. Genotype, of coarse, 1a---gene, CT, of coarse, CC has a much better response than CT.
My dilemna-----My insurance is refusing incivek {d/t price difference}. Yet, everything I read indicates that there is a significant difference in success rates between the two drugs, with incivek having the higher rate.
I do have some options----- I could fight my insurance company-with a minimum of a 6 month decision time line. I could ask the manufacturer for assistance.
I understand at stage 3+ that I will require a transplant before any future drugs could be approved.
So, placing side effects into the background-place both drugs on respond/non-respond scales, as equal as the trials will allow.....Which drug has the higher statistical success rate?
I'm a non-responder to the previous treatment. Geno 1a, same as you. I'm on Victrelis and I'm happy that my doc & I chose that drug for me. The SVR rates are approximately the same between both drugs. It's not an easy treatment no matter which path you take, but according to the experiences related on this forum, Victrelis has fewer side effects but a longer treatment duration. I just found out that I am undetectable after only 4 weeks on the Vic, I never thought I would see the day!!! Incidentally, I just spoke to my doc about this, and all 5 of his patients currently on Victrelis have had their viral load drop to undetectable by that 4 week mark. So please don't fret if you get "stuck" doing that drug due to insurance reasons. It's working for us non-responders!
Best of luck and feel free to ask any questions, we're all here for you.
aloha.
-Kim
I am not aware of any obviously better performance from Incivek or Victrelis. That is not to say that there aren't minor differences, but the folks around here that are using Victrelis are enjoying incredible success rates, without many of the more objectionable side effects from Incivek. I am an Incivek veteran, and I would rather be poked in the eye than go through that again. It worked great, but it hurt me.
Alan
I am a non-responder x2. My last bx (biopsy) was approximately one month ago. Bx reveals stage 3. Genotype, of coarse, 1a---gene, CT, of coarse, CC has a much better response than CT.
My dilemna-----My insurance is refusing incivek {d/t price difference}. Yet, everything I read indicates that there is a significant difference in success rates between the two drugs, with incivek having the higher rate.
I do have some options----- I could fight my insurance company-with a minimum of a 6 month decision time line. I could ask the manufacturer for assistance.
I understand at stage 3+ that I will require a transplant before any future drugs could be approved.
So, placing side effects into the background-place both drugs on respond/non-respond scales, as equal as the trials will allow.....Which drug has the higher statistical success rate?
Thank you,
Mia